XERS Xeris Biopharma Holdings, Inc. Stock Quote

XERS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	2.70%	Shs Outstand	135.03M	Perf Week	-19.01%
Market Cap	269.34M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	2.45%	Shs Float	132.05M	Perf Month	-19.01%
Income	-138.00M	PEG	-	EPS next Q	-0.25	Inst Own	41.10%	Short Float	4.10%	Perf Quarter	-12.50%
Sales	63.50M	P/S	4.24	EPS this Y	27.30%	Inst Trans	23.76%	Short Ratio	2.99	Perf Half Y	-9.26%
Book/sh	0.71	P/B	2.76	EPS next Y	51.80%	ROA	-59.70%	Target Price	6.25	Perf Year	-40.61%
Cash/sh	0.96	P/C	2.04	EPS next 5Y	-	ROE	-264.00%	52W Range	1.25 - 4.98	Perf YTD	-33.11%
Dividend	-	P/FCF	-	EPS past 5Y	-18.30%	ROI	-62.80%	52W High	-61.04%	Beta	1.61
Dividend %	-	Quick Ratio	2.40	Sales past 5Y	115.20%	Gross Margin	72.00%	52W Low	55.20%	ATR	0.21
Employees	294	Current Ratio	2.70	Sales Q/Q	169.50%	Oper. Margin	-	RSI (14)	42.06	Volatility	7.96% 11.47%
Optionable	Yes	Debt/Eq	1.43	EPS Q/Q	16.90%	Profit Margin	-	Rel Volume	0.35	Prev Close	1.96
Shortable	Yes	LT Debt/Eq	1.43	Earnings	May 11 BMO	Payout	-	Avg Volume	1.81M	Price	1.94
Recom	1.70	SMA20	-8.92%	SMA50	-19.15%	SMA200	-17.03%	Volume	500,030	Change	-1.02%

Apr-28-22

Initiated

Craig Hallum

Buy

$6.50

Nov-17-21

Initiated

SVB Leerink

Outperform

Oct-29-21

Initiated

H.C. Wainwright

Buy

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$11

Feb-18-20

Initiated

Piper Sandler

Overweight

$12

Jul-16-18

Initiated

RBC Capital Mkts

Outperform

$24

Jul-16-18

Initiated

Leerink Partners

Outperform

$24

Jul-16-18

Initiated

Jefferies

Buy

$23

May-12-22 04:02PM	Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushings Syndrome Data at AACE Annual Meeting May 12-14 Business Wire -7.32%
May-11-22 07:00AM	Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events Business Wire -8.38%
May-04-22 08:00AM	Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022 Business Wire
Mar-23-22 10:34AM	10 Stocks I'm Watching in 2022: An Update TheStreet.com
Mar-16-22 07:00AM	Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above Business Wire
Mar-10-22 07:00AM	Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events Business Wire +6.07%
06:55AM	Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital Business Wire
Mar-04-22 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 Business Wire
Mar-01-22 03:00PM	Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-09-22 07:00AM	Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference Business Wire
Jan-31-22 07:00AM	Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushings Syndrome Business Wire
Jan-13-22 08:55AM	PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome PR Newswire
Jan-07-22 10:13AM	Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options Zacks
Jan-06-22 07:00AM	Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference Business Wire
Jan-03-22 07:00AM	Xeris Biopharma Enters Into Agreement for $30 Million Private Placement Business Wire
Dec-31-21 03:10PM	Moderna's on the Rise, but This Small Biotech Is the Nasdaq's Big Winner on New Year's Eve Motley Fool +20.58%
01:42PM	Here's Why Xeris Biopharma Stock Is Jumping Today Motley Fool
12:51PM	XERS Stock Pops on Huge FDA News. Heres What to Know. InvestorPlace
08:52AM	Xeris Biopharma soars on premarket leading volume after FDA approval of Cushing's syndrome treatment MarketWatch
Dec-30-21 04:30PM	Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushings Syndrome Business Wire
Dec-16-21 07:00AM	Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma Business Wire
Dec-06-21 08:34AM	Implied Volatility Surging for Xeris (XERS) Stock Options Zacks
Nov-18-21 08:30AM	Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer GlobeNewswire
Nov-10-21 07:00AM	Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights Business Wire
Nov-02-21 07:30AM	Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021 Business Wire
Nov-01-21 03:02PM	Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should Know Zacks +5.91%
Oct-29-21 12:38PM	Why Xeris Pharmaceuticals Is Soaring 7% Higher Today Motley Fool
Oct-25-21 07:30AM	Xeris Pharmaceuticals Enters Collaboration Agreement With Merck Business Wire +5.49%
Oct-05-21 04:05PM	Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma Business Wire
04:01PM	Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. GlobeNewswire
Oct-04-21 10:49AM	Hedge Funds Are Selling Xeris Pharmaceuticals, Inc. (XERS) Insider Monkey
Oct-01-21 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-22-21 11:37AM	How Much Of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Do Institutions Own? Simply Wall St.
Sep-17-21 08:00AM	Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Wire
Sep-15-21 07:38AM	The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga
Sep-14-21 04:05PM	Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma Business Wire
Sep-08-21 04:01PM	Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc. GlobeNewswire
Sep-07-21 04:05PM	Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire
Sep-01-21 07:30AM	Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121) Business Wire
Aug-31-21 07:30AM	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote FOR the Transaction With Xeris GlobeNewswire
Aug-30-21 07:30AM	Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote "FOR" the Transaction With Strongbridge Biopharma Business Wire
07:30AM	Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote FOR the Transaction With Xeris GlobeNewswire
Aug-25-21 07:02AM	21 Stocks Moving in Wednesday's Pre-Market Session Benzinga
Aug-23-21 03:40PM	Why Xeris Pharmaceuticals Shares Traded Higher Today Benzinga +21.36%
12:01PM	35 Stocks Moving In Monday's Mid-Day Session Benzinga
08:00AM	Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia Business Wire
06:54AM	Xeris Stock Jumps on FDA Clearance of Hypoglycemia Treatment TheStreet.com
Aug-19-21 08:00AM	Xeris Pharmaceuticals Strengthens Its Patent Estate Business Wire
Aug-13-21 08:00AM	Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke® Business Wire
Aug-11-21 04:05PM	Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol Levothyroxine (XP-8121) for the Treatment of Hypothyroidism Business Wire
Aug-08-21 04:06AM	Things Look Grim For Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) After Today's Downgrade Simply Wall St.
Aug-05-21 09:15AM	Xeris Pharmaceuticals (XERS) Reports Q2 Loss, Misses Revenue Estimates Zacks -12.98%
07:00AM	Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights Business Wire
Jul-29-21 04:05PM	Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue Business Wire -5.37%
08:30AM	Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021 Business Wire
Jul-28-21 04:15PM	Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success Business Wire
Jul-19-21 09:53AM	Xeris Pharma, Tetris Ink Commercialization Pact For Ogluo In Europe Benzinga
08:00AM	Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe Business Wire
Jul-02-21 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-29-21 10:15AM	Form 8.3 - Xeris Pharmaceuticals, Inc. Business Wire
Jun-28-21 10:15AM	Form 8.3 - Xeris Pharmaceuticals, Inc. Business Wire -6.86%
Jun-16-21 08:32AM	Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options Zacks
Jun-15-21 07:56AM	Is Xeris Pharmaceuticals (NASDAQ:XERS) Using Too Much Debt? Simply Wall St. +5.34%
Jun-05-21 03:55PM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALTA, XERS, ONB, FFWM; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Jun-04-21 07:00PM	Lifshitz Law Firm, P.C. Announces Investigation of CLDR, DTRCD, DCRN, ENVB, PACX, SNX, XERS, and SBBP PR Newswire +5.19%
Jun-01-21 06:20PM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TLND, XERS, SNX, FI, HGV, STAY; Shareholders are Encouraged to Contact the Firm PR Newswire
May-31-21 08:30PM	SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Xeris Pharmaceuticals, Inc. (XERS) and Encourages Stockholders to Contact the Firm ACCESSWIRE
May-28-21 06:01PM	Lifshitz Law Firm, P.C. Announces Investigation of DRTC, EQT, HCIC, MDP, MMAC, NTWN, SNX, XERS and SBBP PR Newswire
May-27-21 11:45AM	INVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, INSW, LMNX, XERS; Shareholders are Encouraged to Contact the Firm ACCESSWIRE
May-25-21 11:13AM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Strongbridge Biopharma plc Merger GlobeNewswire
10:42AM	Strongbridge Shares Jump 12% on Acquisition Deal with Xeris SmarterAnalyst
May-24-21 06:30PM	Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm XERS Business Wire -5.76%
04:58PM	Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases PR Newswire
12:43PM	STRONGBRIDGE BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBBP and Encourages Investors to Contact the Firm GlobeNewswire
07:57AM	Strongbridge Shares Shoot Higher After Xeris' Buyout Deal At $267M Benzinga
07:28AM	5 Top Stock Gainers for Monday: Virgin Galactic, Beyond Meat, Tesla TheStreet.com
07:00AM	Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases Business Wire
06:55AM	Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases Business Wire
05:46AM	Xeris Pharmaceuticals to Buy Strongbridge Biopharma for $267 Million TheStreet.com
May-17-21 08:20AM	Silver Elephant Plans to Announce Minago Nickel Project Mineral Resource Estimate in June For Nickel Spinout ACCESSWIRE
May-13-21 12:11PM	Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights Business Wire
May-10-21 04:05PM	Xeris Pharmaceuticals to Webcast Upcoming Presentations Business Wire
May-06-21 04:05PM	Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021 Business Wire
08:00AM	Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank Business Wire
Apr-29-21 05:05PM	Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
04:05PM	Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus Business Wire
Apr-28-21 08:08AM	Does Xeris Pharmaceuticals' (NASDAQ:XERS) Share Price Gain of 70% Match Its Business Performance? Simply Wall St.
Apr-12-21 12:23PM	With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors? Motley Fool -7.09%
Apr-01-21 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-23-21 12:22PM	2 Strong Buy Penny Stocks With Massive Upside Ahead TipRanks
09:14AM	Need To Know: Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Insiders Have Been Buying Shares Simply Wall St.
Mar-14-21 08:22PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS Newsfile
Mar-12-21 05:35AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS PR Newswire
05:35AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS CNW Group
Mar-11-21 07:00AM	Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering Business Wire +13.82%
Mar-10-21 12:00PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Xeris Pharmaceuticals, Inc. (XERS) and Encourages Investors to Contact the Firm ACCESSWIRE -5.86%
02:35AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS PR Newswire
02:35AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS CNW Group
Mar-09-21 08:15AM	Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates Zacks

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Edick Paul R	See Remarks	May 12	Buy	1.40	100,000	140,380	1,508,064	May 13 04:19 PM
PRESTRELSKI STEVEN	Chief Scientific Officer	Feb 22	Option Exercise	0.69	11,228	7,747	581,008	Feb 24 04:28 PM
PRESTRELSKI STEVEN	Chief Scientific Officer	Feb 22	Sale	2.42	11,228	27,158	569,780	Feb 24 04:28 PM
Edick Paul R	See Remarks	Nov 15	Buy	2.28	20,000	45,664	33,430	Nov 16 04:25 PM
Shannon John Patrick Jr	See Remarks	Nov 12	Buy	2.10	60,000	126,000	363,829	Nov 12 05:12 PM
Shannon John Patrick Jr	See Remarks	Nov 11	Buy	2.09	40,000	83,500	303,829	Nov 12 05:12 PM
Edick Paul R	See Remarks	Nov 11	Buy	2.08	200,000	415,760	808,064	Nov 12 05:09 PM
Pieper Steven	See Remarks	Nov 10	Buy	2.00	25,000	49,918	183,108	Nov 12 05:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience